Coming December: ASH publishes its late-breaking abstracts. We’ll add the organizations presenting them.

Merck & Co. at ASH 2026

Dec 12–15, 2026 New Orleans, LA ~30k attendees Website

Merck & Co. brings 3 presentations to ASH 2026 in New Orleans, and exhibits at Booth 2639. Merck supports a symposium on polycythemia vera and myeloproliferative neoplasm care. Its research covers the LSD1 inhibitor bomedemstat for sickle cell disease and fatigue measures in essential thrombocythemia.

OrganizationASH 2026 Attendance
Merck & Co.
Rahway, NJ
Large pharma
Global pharmaceutical company, known as MSD outside the US and Canada, with a broad oncology clinical research program spanning many tumor types.
Booth
Exhibiting at Booth 2639
Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm
Symposium
Fri Dec 11
7:00pm–10:00pm
From Evidence to Action in MPN: Transforming Challenges to Opportunities in PV and ET Patients
Treatment options for polycythemia vera and essential thrombocythemia after first-line therapy fails, including new targeted drugs for patients with unmet needs.
Symposium hosted by Answers in CME
Leukemias

Explore the full ASH 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in New Orleans. Leave your work email and we’ll be in touch.

Privacy

Download the full ASH 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find decision makers at Merck & Co.

Tell us what you sell and we’ll find the people at Merck & Co. most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction